Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Levocabastine is a long acting, highly potent and selective histamine H1-receptor antagonist, which has been developed for nasal and ocular administration. In controlled trials performed to date levocabastine was effective and well tolerated in the treatment of allergic rhinitis and allergic conjunctivitis. Comparative studies have demonstrated that levocabastine is superior to placebo and at least as effective as sodium cromoglycate (cromolyn sodium) in alleviating symptoms associated with seasonal allergic conditions. Although levocabastine appears to be less effective than the topical corticosteroid beclomethasone with regard to relieving runny and blocked nose, further comparative trials between these 2 agents would be desirable. Similar to other antihistamines, levocabastine provides minimal relief of nasal blockage, but this symptom is believed to be mediated by receptors other than histamine H1. The prompt onset of antiallergic activity after application differentiates levocabastine from the reference topical antiallergic, sodium cromoglycate, which has an onset of efficacy characterised by a lag period, thereby necessitating maintenance treatment. The incidence of adverse effects associated with levocabastine therapy is low and is similar to that observed with placebo and sodium cromoglycate.
Levocabastine provides prophylactic protection as well as acute relief from nasal and ocular symptoms in patients with seasonal allergic disorders. With the ever increasing trend towards topical therapy for the treatment of allergic rhinitis and allergic conjunctivitis, levocabastine is a useful addition to the range of drugs currently available. Possible avenues for additional research should include determining whether the antiallergic efficacy of topical levocabastine is superior to that of oral agents such as astemizole and terfenadine, and whether topical therapy is indeed preferred, considering the relative ease of administration of effective oral antiallergic agents.
In vitro receptor binding techniques and drug-receptor dissociation assays have shown that levocabastine has highly specific and potent antihistaminic H1-receptor activity but displays little or no affinity for serotoninergic, dopaminergic, adrenergic or μ-opiate receptor sites. Standard pharmacological tests of antihistaminic activity in animals — such as death caused by histamine and compound 48/80, and histamine-induced skin reaction, bronchoconstriction and conjunctivitis — have established the potency of levocabastine after oral and ocular administration. In humans, levocabastine 0.05% eyedrops displayed potent topical antihistaminic activity in conjunctival provocation tests.
Levocabastine had the highest potency among 12 reference compounds tested for antiallergic activity in Ascaris-hypersensitive dogs, and its effects were sustained for 16 to 30 hours. Nasal and conjunctival provocation testing with allergens in humans has clearly demonstrated the antiallergic activity of levocabastine when it is applied as a topical nasal spray or as eyedrops. Protection from allergen-induced symptoms was observed within 5 minutes following drug application.
In a few studies of central nervous system (CNS) activity and psychomotor performance testing in healthy volunteers, topically applied levocabastine did not induce electroencephalographic (EEG) changes, impair psychomotor function or potentiate the central affects of depressant drugs such as diazepam.
Levocabastine nasal spray was shown to have no effect on ciliary beat frequency or mucociliary transit time. In ophthalmological examinations in volunteers and atopic patients, levocabastine eyedrops produced minimal or no ocular irritation.
Absorption of topical levocabastine occurs within 1 to 2 hours after administration and is incomplete; bioavailability following intranasal or ocular application was found to be between 60 and 80% and 30 and 60%, respectively, in volunteers. Nasal absorption appears to be lower in patients with allergic rhinitis. Following administration of single oral doses of levocabastine, peak plasma concentrations were attained in approximately 2 hours and systemic bioavailability was 100%. Steady-state plasma concentrations were achieved in 7 to 10 days with multiple-dose administration of levocabastine, and measured approximately 10.4 μg/L with nasal spray and 1.6 μg/L with eyedrops.
The hepatic metabolism of levocabastine is of relatively minor significance. In humans, 65 to 70% of absorbed levocabastine is excreted in the urine as unchanged drug, 10 to 20% appears in the faeces unchanged, and the remainder is recovered in the urine as the acylglucuronide metabolite. The elimination half-life of levocabastine was found to be between 35 and 40 hours and is similar after single- or multiple-dose administration, indicating that no accumulation of drug occurs. The plasma protein binding of levocabastine is approximately 55%, with most drug bound to albumin.
Levocabastine pharmacokinetics are similar in adults and children. Because of limited metabolism, hepatic impairment is unlikely to affect the disposition of this newer agent. In renally impaired patients, however, the absorption of an oral dose of levocabastine 0.5mg was reduced and the elimination half-life was prolonged compared with healthy controls.
Levocabastine has been evaluated in clinical trials involving patients with allergic rhinitis (both seasonal and perennial) and/or seasonal allergic conjunctivitis. Global evaluations of the drug in alleviating the symptoms of allergic rhinitis showed that, in general, a higher percentage of patients had an ‘excellent’ or ‘good’ response to levocabastine than to placebo or sodium cromoglycate. Scores by patients and investigators to rate the severity of individual symptoms of allergic rhinitis were typically lower with levocabastine than with placebo or sodium cromoglycate. However, the symptom of nasal obstruction did not respond well to any of the study medications, suggesting that mediators other than histamine are likely to be involved. A single-blind study incorporating small numbers of patients found levocabastine to be less effective than beclomethasone in relieving runny and blocked nose in patients with allergic rhinitis.
In a few studies investigating the efficacy of levocabastine nasal spray in the treatment of patients with perennial allergic (and nonallergic) rhinitis, levocabastine was significantly superior to placebo and similar in efficacy to sodium cromoglycate or beclomethasone.
In patients with seasonal allergic conjunctivitis, the efficacy of levocabastine eyedrops was superior to that of placebo in spite of a frequently high placebo response rate. Levocabastine was at least as effective as and, in some instances, was slightly more effective than sodium cromoglycate in the prophylaxis and treatment of ocular symptoms associated with allergic conjunctivitis, under both high and low pollen count conditions. A few long term studies demonstrated that the antiallergic activity of levocabastine was maintained during continued use.
Combination therapy with nasal and ocular formulations of levocabastine was evaluated in patients with allergic rhinoconjunctivitis. The differences between levocabastine and sodium cromoglycate did not reach statistical significance. While levocabastine and flunisolide nasal therapy received comparable ratings by patients, a significantly larger proportion of patients preferred ocular levocabastine to antazoline/naphazoline eyedrops.
Levocabastine is well tolerated and has an adverse effect profile comparable to placebo and sodium cromoglycate. In patients treated with topical nasal therapy, nasal irritation has been the most frequently reported adverse effect, with an incidence of 5.4, 5.6 and 6% among those receiving levocabastine, placebo and sodium cromoglycate, respectively. The incidence of somnolence was 3.8, 3.5 and 3.3%, respectively, and dry mouth was 3.3, 2.6 and 2.7%, respectively.
In patients receiving levocabastine eyedrops, ocular irritation was reported by 16.4%. This was similar to that reported by patients receiving placebo (15.8%) and sodium cromoglycate (15.6%). The incidence of headache was 3.5% in patients receiving ocular levocabastine, 4.2% in placebo recipients and 6.5% in patients treated with sodium cromoglycate.
Dosage and Administration
The minimum effective dosage of levocabastine 0.5 mg/ml nasal spray in the treatment of patients with allergic rhinitis is 2 sprays into each nostril twice daily. In the treatment of allergic conjunctivitis, the minimum effective dose of levocabastine 0.5 mg/ml eyedrops is 1 drop into each eye twice daily. The frequency of administration may be increased to 3 or 4 times daily if necessary.
- Abelson MB, Smith LM. Levocabastine: evaluation in the histamine and compound 48/80 models of ocular allergy in humans. Ophthalmology 95: 1494–1497, 1988
- Arriaga F, Rombaut N. Absence of central effects with levocabastine eye drops. Allergy, in press, 1990
- Awouters F, Vermeire J, Smeyers F, Vermote P, Van Beek R, et al. Oral antiallergic activity in ascaris hypersensitive dogs: a study of known antihistamines and of the new compounds ramastine (R 57 959) and levocabastine (R 50 547). Drug Development Research 8: 95–102, 1986 CrossRef
- Bende M, Pipkorn U. Topical levocabastine, a selective H1 antagonist, in seasonal allergic rhinoconjunctivitis. Allergy 42: 512–515, 1987 CrossRef
- Ciprandi G, Cerqueti PM, Sacca S, et al. Levocabastine versus cromolyn sodium in the treatment of pollen-induced conjunctivitis. Annals of Allergy 65: 156–158, 1990
- Connell JT. Methods of studying antihistamines. NER Allergy Proceedings 7: 346–355, 1986 CrossRef
- Feinberg G, Stokes TC. Application of histamine-induced conjunctivitis to the assessment of a topical antihistamine, levocabastine. International Archives of Allergy and Applied Immunology 82: 537–538, 1987 CrossRef
- Heykants J, Van Peer A, Woestenborghs R, Geuens I, Rombaut N, et al. Pharmacokinetics and bioavailability of levocabastine (R 50547) in man. Archives Internationales de Pharmacodynamie et de Therapie 274: 329–330, 1985
- Holmberg K, Pipkorn U, Bake B, Blychert L-O. Effects of topical treatment with H1 and H2 antagonists on clinical symptoms and nasal vascular reactions in patients with allergic rhinitis. Allergy 44: 281–287, 1989 CrossRef
- Howarth PH, Holgate ST. Comparative trial of two non-sedative H1 antihistamines, terfenadine and astemizole, for hay fever. Thorax 39: 668–672, 1984 CrossRef
- Jackson RT, Todd NW, Turner Jr JS. Ear, nose and throat diseases. In Speight TM (Ed.) Avery’s drug treatment, 3rd ed., ADIS Press, Auckland, 1987
- Janssens MM-L, Vanden Bussche G. Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis. Presented at the Annual Meeting of the European Academy of Allergology and Clinical Immunology: Topical allergy treatment in the 90s, Glasgow, July 11, 1990
- Kolly M, Pécoud A. Comparison of levocabastine, a new selective H1-receptor antagonist, and disodium cromoglycate, in a nasal provocation test with allergen. British Journal of Clinical Pharmacology 22: 389–394, 1986 CrossRef
- Leysen JE, Gommeren W. Drug-receptor dissociation time, new tool for drug research: receptor binding affinity and drug-receptor dissociation profiles of serotonin-S2, dopamine-D2, histamine-H1 antagonists, and opiates. Drug Development Research 8: 119–131, 1986 CrossRef
- Odelram H, Björkstén B, Klercker TA, Rimås M, Kjellman N-IM, et al. Topical levocabastine versus sodium cromoglycate in allergic conjunctivitis. Allergy 44: 432–436, 1989 CrossRef
- Palma-Carlos AG, Palma-Carlos ML, Rombaut N. The effect of levocabastine nasal spray in nasal provocation tests. International Journal of Clinical Pharmacology Research 8: 25–30, 1988
- Pipkorn U, Bende M, Hedner J, Hedner T. A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis. Allergy 40: 491–496, 1985 CrossRef
- Rimås M, Kjellman N-IM, Blychert L-O, Björkstén B. Topical levocabastine protects better than sodium cromoglycate and placebo in conjunctival provocation tests. Allergy 45: 18–21, 1990 CrossRef
- Schata M, Jorde W, Kersten W, Olzem R, Bauer R, et al. Double-blind comparison of levocabastine nasal spray with sodium cromoglycate and placebo in the topical treatment of seasonal allergic rhinitis. In Mygind N & Naclerio RM (Eds) Rhinoconjunctivitis: new perspectives in topical treatment. Proceedings of the XIIIth International Congress of Allergology and Clinical Immunology, Montreux, Oct 1988, pp. 43–48, Hogrefe & Huber Publishers, 1989
- Sorkin EM, Ward A. Ocular sodium cromoglycate: an overview of its therapeutic efficacy in allergic eye disease. Drugs 31: 131–148, 1986 CrossRef
- Stokbroekx RA, Luyckx MGM, Willems JJM, Janssen M, Bracke-JOMM, et al. Levocabastine (R 50547): the prototype of a chemical series of compounds with specific H1-antihistaminic activity. Drug Development Research 8: 87–93, 1986 CrossRef
- van de Heyning PH, van Haesendonck J, Creten W, Rombaut N. Effect of topical levocabastine on allergic and non-allergic perennial rhinitis: a double-blind study, levocabastine vs. placebo, followed by an open, prospective, single-blind study on beclomethasone. Allergy 43: 386–391, 1988 CrossRef
- Vanden Bussche G. Levocabastine hydrochloride. Drugs of the Future 11: 841–843, 1986
- Van Wauwe JP. Animal pharmacology of levocabastine: a new type of H1-antihistamine well suited for topical application. In Mygind N & Naclerio RM (Eds). Rhinoconjunctivitis: new perspectives in topical treatment. Proceedings of the XIIIth International Congress of Allergology and Clinical Immunology, Montreux, Oct 1988, pp. 27–34, Hogrefe & Huber Publishers, 1989
- Zawodnik S, Petitpierre M, de Wurstemberger B. Levocabastine and DSCG in allergic conjunctivitis. XIII International Congress of Allergology and Clinical Immunology, Montreux, Switzerland, October 16–21, 1988. New England and Regional Allergy Proceedings 9: 334, 1988
- Zuber P, Pécoud A. Effect of levocabastine, a new H1 antagonist, in a conjunctival provocation test with allergens. Journal of Allergy and Clinical Immunology 82: 590–594, 1988 CrossRef
Volume 41, Issue 2 , pp 202-224
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors